(19)
(11) EP 1 222 929 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.07.2010 Bulletin 2010/27

(45) Mention of the grant of the patent:
19.05.2010 Bulletin 2010/20

(21) Application number: 02447005.6

(22) Date of filing: 11.01.2002
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
 A61P 7/02(2006.01)

(54)

Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome

Verfahren und pharmazeutische Zusammensetzung zur Vorbeugung und/oder Behandlung des Syndroms der systemischen entzündlichen Reaktion

Procédé et composition pharmaceutique pour la prévention et/ou le traitement du syndrome de réponse inflammatoire systémique

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 11.01.2001 US 261405 P

(43) Date of publication of application:
17.07.2002 Bulletin 2002/29

(73) Proprietor: Life Sciences Research Partners VZW
3000 Leuven (BE)

(72) Inventors:
  • Jacquemin, Marc G.
    5330 Sart-Bernard (BE)
  • Saint-Remy, Jean-Marie R.
    1390 Grez-Doiceau (BE)

(74) Representative: Bird, William Edward et al
Bird Goën & Co. Klein Dalenstraat 42A
3020 Winksele
3020 Winksele (BE)


(56) References cited: : 
WO-A-01/04269
 WO-A-97/26010
   
  • JACQUEMIN M ET AL: "A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor" BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 95, no. 1, 1 January 2000 (2000-01-01), pages 156-163, XP002150704 ISSN: 0006-4971
  • JACQUEMIN M G ET AL: "MECHANISM AND KINETICS OF FACTOR VIII INACTIVATION: STUDY WITH AN IGG4 MONOCLONAL ANTIBODY DERIVED FROM A HEMOPHILIA A PATIENT WITH INHIBITOR" BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 92, no. 2, 1998, pages 496-506, XP000906844 ISSN: 0006-4971
  • SAINT-REMY JEAN-MARIE R: "B- and T-cell tolerance: From basic concepts to clinical practice." HAEMATOLOGICA, vol. 85, no. 10 Suppl., October 2000 (2000-10), pages 93-96, XP008006242 ISSN: 0390-6078
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).